In the 20th century, we learned that healthy lifespan is malleable. The scientific pathways behind this effect are incredibly complex and difficult to correctly control, but manipulating them may lead to new treatments for age-related disease. We want to get these therapeutic advances translated safely to patients as quickly as possible. Longevity Fund companies have collected >$500M in follow-on funding, resulting in the 2018 IPO of the first company dedicated to reversing the diseases of aging, and multiple programs in clinic to reverse or prevent age-related disease.